JP2020531543A5 - - Google Patents

Download PDF

Info

Publication number
JP2020531543A5
JP2020531543A5 JP2020511528A JP2020511528A JP2020531543A5 JP 2020531543 A5 JP2020531543 A5 JP 2020531543A5 JP 2020511528 A JP2020511528 A JP 2020511528A JP 2020511528 A JP2020511528 A JP 2020511528A JP 2020531543 A5 JP2020531543 A5 JP 2020531543A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
oral pharmaceutical
hours
subject
amantadine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020511528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531543A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/047754 external-priority patent/WO2019040748A1/en
Publication of JP2020531543A publication Critical patent/JP2020531543A/ja
Publication of JP2020531543A5 publication Critical patent/JP2020531543A5/ja
Priority to JP2022183927A priority Critical patent/JP2023009251A/ja
Priority to JP2024139596A priority patent/JP2024159885A/ja
Pending legal-status Critical Current

Links

JP2020511528A 2017-08-24 2018-08-23 アマンタジン組成物、その調製、および使用方法 Pending JP2020531543A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022183927A JP2023009251A (ja) 2017-08-24 2022-11-17 アマンタジン組成物、その調製、および使用方法
JP2024139596A JP2024159885A (ja) 2017-08-24 2024-08-21 アマンタジン組成物、その調製、および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762549921P 2017-08-24 2017-08-24
US62/549,921 2017-08-24
PCT/US2018/047754 WO2019040748A1 (en) 2017-08-24 2018-08-23 AMANTADINE COMPOSITIONS, THEIR PREPARATION, AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022183927A Division JP2023009251A (ja) 2017-08-24 2022-11-17 アマンタジン組成物、その調製、および使用方法

Publications (2)

Publication Number Publication Date
JP2020531543A JP2020531543A (ja) 2020-11-05
JP2020531543A5 true JP2020531543A5 (https=) 2021-09-24

Family

ID=65439620

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020511528A Pending JP2020531543A (ja) 2017-08-24 2018-08-23 アマンタジン組成物、その調製、および使用方法
JP2022183927A Pending JP2023009251A (ja) 2017-08-24 2022-11-17 アマンタジン組成物、その調製、および使用方法
JP2024139596A Pending JP2024159885A (ja) 2017-08-24 2024-08-21 アマンタジン組成物、その調製、および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022183927A Pending JP2023009251A (ja) 2017-08-24 2022-11-17 アマンタジン組成物、その調製、および使用方法
JP2024139596A Pending JP2024159885A (ja) 2017-08-24 2024-08-21 アマンタジン組成物、その調製、および使用方法

Country Status (10)

Country Link
US (3) US11077073B2 (https=)
EP (1) EP3672581A4 (https=)
JP (3) JP2020531543A (https=)
CN (2) CN117860718A (https=)
AU (2) AU2018320946B2 (https=)
BR (1) BR112020003375A2 (https=)
CA (1) CA3072764A1 (https=)
IL (1) IL272834B2 (https=)
MX (2) MX2020002078A (https=)
WO (1) WO2019040748A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2994873A1 (en) 2009-12-02 2011-06-09 Adamas Pharma, Llc Amantadine compositions and methods of use
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
AU2018320946B2 (en) 2017-08-24 2024-05-02 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
US11441653B1 (en) 2021-05-20 2022-09-13 Dana Automotive Systems Group, Llc Integrated gearbox in electric motor systems

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JP2623099B2 (ja) 1987-11-06 1997-06-25 株式会社ニフコ スライダの引込み装置
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
DK469989D0 (da) 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5190763A (en) 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
US5358721A (en) 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
AU3404997A (en) 1996-05-31 1998-01-05 Euro-Celtique S.A. Sustained release oxycodone formulations with no fed/fast effect
US5849800A (en) 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1239840B1 (en) 1999-12-09 2005-04-06 Alza Corporation Antiviral medication
AP1748A (en) 2001-03-13 2007-06-11 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms.
US20060198815A1 (en) 2001-03-19 2006-09-07 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
DE10129265A1 (de) 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
EP1416919A1 (en) 2001-07-17 2004-05-12 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US20030045577A1 (en) 2001-08-15 2003-03-06 Madhat Maher N. Method for preventing infectious respiratory diseases
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20040102525A1 (en) 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
PT1509232E (pt) 2002-05-31 2009-01-07 Lundbeck & Co As H Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
EP1524981B1 (en) 2002-07-29 2009-03-11 Glaxo Group Limited Sustained release formulations comprising lamotrigine
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
TW200418446A (en) 2002-10-24 2004-10-01 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US20060024366A1 (en) 2002-10-25 2006-02-02 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20040121010A1 (en) 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
AU2003301121A1 (en) 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
AR043467A1 (es) 2003-03-05 2005-07-27 Osmotica Argentina S A Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
MXPA06003101A (es) 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis cronoterapeuticas.
US8389008B2 (en) 2003-09-19 2013-03-05 Penwest Pharmaceuticals Co. Delayed release dosage forms
WO2005079779A1 (en) 2003-10-22 2005-09-01 Merz Pharma Gmbh & Co. Kgaa THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES
US20050119249A1 (en) 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7211275B2 (en) 2004-01-16 2007-05-01 Massachusetts Institute Of Technology Composite materials for controlled release of water soluble products
EP1715843A1 (en) 2004-01-29 2006-11-02 Neuromolecular Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
WO2005079773A2 (en) 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
DK1742624T3 (da) 2004-02-18 2010-03-08 Sepracor Inc Dopamin-agonist-kombinationsterapi med sedativer til forbedring af søvnkvalitet
TW200531680A (en) 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
EA011446B1 (ru) 2004-06-17 2009-02-27 Форест Лэборэтериз, Инк. Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
JP2006079138A (ja) 2004-09-07 2006-03-23 Ricoh Co Ltd ステータス取得方法、プリンタドライバ及び情報処理装置
CA2588295C (en) 2004-11-23 2013-10-22 Adamas Pharma, Llc Method and composition for administering an nmda receptor antagonist to a subject
US20190008799A1 (en) 2004-11-23 2019-01-10 Adamas Pharma, Llc Composition for administering an nmda receptor antagonist to a subject
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP2623099A1 (en) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition and method for treating neurological disease
US20190328684A1 (en) 2004-11-24 2019-10-31 Adamas Pharma, Llc Composition and method for treating neurological disease
US8252331B2 (en) 2004-12-03 2012-08-28 Osmotica Kereskedelmi és Szolgáltató, KFT Osmotic device containing amantadine and an osmotic salt
US8574626B2 (en) 2004-12-03 2013-11-05 Osmotica Kereskedelmi és Szolgáltató KFT Osmotic device containing amantadine and an osmotic salt
AR053986A1 (es) * 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US20080279819A1 (en) 2005-02-15 2008-11-13 Adamas Pharmaceuticals, Inc. Combinations Therapy for Treatment of Demyelinating Conditions
ATE481096T1 (de) 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
US8920837B2 (en) 2005-07-01 2014-12-30 Rubicon Research Private Limited Sustained release dosage form
EP1942875B1 (en) 2005-08-24 2015-08-12 Rubicon Research Private Limited Controlled release formulation
US20070104778A1 (en) 2005-11-07 2007-05-10 Hongxia Zeng Controlled-release emulsion compositions
US20080089861A1 (en) 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
CA2662123C (en) 2006-08-30 2015-12-01 Jagotec Ag Controlled release oral dosage formulations comprising a core and one or more barrier layers
EP1961414A1 (en) 2007-02-21 2008-08-27 FUJIFILM Manufacturing Europe B.V. A controlled release composition comprising a recombinant gelatin
WO2008106429A2 (en) * 2007-02-26 2008-09-04 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
US7981930B2 (en) 2007-03-13 2011-07-19 Adamas Pharmaceuticals, Inc. Compositions and kits for treating influenza
CN103977003A (zh) 2007-04-02 2014-08-13 帕金森氏病研究院 用于降低治疗的副作用的方法和组合物
EP1987815A1 (en) 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
CA2689101C (en) 2007-05-30 2013-01-22 Neos Therapeutics, Lp Modifying drug release in suspensions of ionic resin systems
US8247438B2 (en) * 2008-02-27 2012-08-21 Neuropill, Inc. Methods for treating schizophrenia
US20110142905A1 (en) 2008-08-14 2011-06-16 Bioneer A/S Coated tablets with remaining degradation surface over the time
US20100221328A1 (en) * 2008-12-31 2010-09-02 Wertz Christian F Sustained-release formulations
US20130059008A1 (en) 2009-01-23 2013-03-07 Jeffrey L. Atkinson Drying methods for tuning microparticle properties
CA2755808C (en) 2009-03-18 2016-01-19 Evonik Operations Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
CA2756386C (en) 2009-03-23 2019-01-15 Micell Technologies, Inc. Drug delivery medical device
WO2010115015A1 (en) 2009-04-03 2010-10-07 Coating Place, Inc. Modified-release pharmaceutical drug composition
CA2994873A1 (en) 2009-12-02 2011-06-09 Adamas Pharma, Llc Amantadine compositions and methods of use
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
US8895662B2 (en) 2010-12-31 2014-11-25 Eternal Chemical Co., Ltd. Curable composition and method for manufacturing the same
US20130236544A1 (en) * 2012-03-08 2013-09-12 Dr. Reddy's Laboratories Ltd. Stable pharmaceutical compositions of fesoterodine
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US20160228388A1 (en) 2014-11-04 2016-08-11 Adamas Pharmaceuticals, Inc. Methods of administering amantadine compositions
GB201516037D0 (en) 2015-09-10 2015-10-28 Agco Int Gmbh Vehicle axel assembly
AU2018320946B2 (en) 2017-08-24 2024-05-02 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use

Similar Documents

Publication Publication Date Title
TW389696B (en) Accelerated release composition containing bromocriptine
JP2020531543A5 (https=)
US20030212133A1 (en) Gabapentin analogues for sleep disorders
JP2008520736A5 (https=)
EP3843839A1 (en) Methods of normalizing amino acid metabolism
JP2005528430A5 (https=)
JP2018507243A5 (https=)
JP2013512919A5 (https=)
JP2002520277A (ja) 不眠症を治療する方法
JP2023552700A5 (https=)
JP2017533211A5 (https=)
JP2021152060A (ja) アカンプロセートおよびd−サイクロセリンを使用する組み合わせ療法
JP2019513814A5 (https=)
JP2023500032A5 (https=)
JP2017528521A5 (https=)
JP2019218379A5 (https=)
RU2004131214A (ru) Способы лечения когнитивных расстройств
IL272834B2 (en) Amantadine compositions, preparations thereof, and methods of use
JPWO2008090736A1 (ja) アルツハイマー型認知症の予防及び治療のための医薬
JP2022500485A5 (https=)
CN104013638B (zh) 当药黄素及其衍生物的用途
JPH10505087A (ja) 非麻薬性鎮痛剤および無痛エンハンサーを含有する疼痛緩和組成物
JP2019531286A5 (https=)
JPS61286326A (ja) パ−キンソン病治療薬
CN103919774A (zh) 去亚甲基小檗碱在制备降血脂药物中的应用